Research Progress in Alzheimer’s Disease
While scientists have a solid grasp of what Alzheimer’s looks like in the brain, the origins and mechanisms driving the disease remain elusive. At Columbia’s Alzheimer’s Research Center, doctors are working to identify where the disease starts and how it evolves.
Think of it like investigating a house fire—determining the cause amid the aftermath can be quite challenging. Alzheimer’s research parallels this scenario.
“Alzheimer’s is a slowly progressing disorder,” states Dr. Scott Small, director of the center. “By the time we normally examine the brain, it’s difficult to isolate its primary triggers.”
Small is akin to a fire investigator, leading his team in revolutionary efforts to uncover what instigates Alzheimer’s.
He refers to a specific organelle in the cell they are studying, likening it to Grand Central Station in a complex train network. This organelle, the endosome, is the first to fail in Alzheimer’s patients.
Following this analogy, the brain contains millions of these “stations,” each supporting vital functions like thinking, moving, and feeling.
Small has identified a critical issue in this system for Alzheimer’s patients. “When this breaks, it’s like the bubble bursts, leading to severe traffic jams in Grand Central Station,” he explains.
The pressing question remains: can this be repaired?
Small believes it can—his team is actively developing drugs to address the issue, although none have entered human trials yet. “We are indeed working on it,” he adds.
Small’s colleague, Dr. Yasir Qureshi, is also involved, examining brain samples from both mice and deceased Alzheimer’s patients to identify similar problems.
“We can create questions based on our findings from mice studies and then test them in human brains from comparable areas,” Qureshi notes, adding that it’s important to see if results translate effectively.
Replication of findings is one challenge; reversing the damage, or as Qureshi says, “rescuing” processes, is another. “We’ve observed that, through our experiments, we can reinstate certain functionalities present in a healthy brain,” he mentions.
This success with mice gives Qureshi hope that similar results might be achievable in humans. “If this is successful, we’ll conduct further studies in academic settings and partner with industry to explore drug development,” he states.
Collectively, this research fuels Small’s belief that a breakthrough may be imminent. “I am confident we’ll reach a major milestone. It might be two years, or maybe five, but we’re on the verge,” he shares.






